Prognostic parameter in patients having therapy-related myeloid neoplasms after peptide receptor radionuclide therapy (PRRT) and peptide receptor radioligand therapy (PRLT) over 20 years’ experience

Not Applicable

Completed

• Conditions: therapy- related myeloid neoplasmpeptide receptor radionuclide therapy; related myeloid neoplasm, prognostic factor, peptide receptor radionuclide therapy, overall survival, predictor, myelodysplastic syndrome

• Registration Number: TCTR20200428005
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-09-30
• Study Start: 2020-04-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 386

Inclusion Criteria

Patients who had therapy-related myeloid neoplasm after receiving peptide receptor radionuclide therapy and peptide receptor radioligand therapy

Exclusion Criteria

Patient under 18 years old

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival (death, alive status) at the end of the study death or alive status from data record

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A